Product
autologous CD34+ cell transduced with G2SCID vector
1 clinical trial
3 indications
Indication
Severe Combined ImmunodeficiencyIndication
X-linkedIndication
Gene TherapyClinical trial
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan ConditioningStatus: Active (not recruiting), Estimated PCD: 2025-10-01